Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Uehara, Yuriko ^a,b   Oda, Katsutoshi ^b   Ikeda, Yuji ^b   Koso, Takahiro ^a,b   Tsuji, Shingo ^a   Yamamoto, Shogo ^a,b   Asada, Kayo ^b   Sone, Kenbun ^b   Kurikawa, Reiko ^b   Makii, Chinami ^b   Hagiwara, Otoe ^b   Tanikawa, Michihiro ^b   Maeda, Daichi ^b   Hasegawa, Kosei ^c   Nakagawa, Shunsuke ^d   Wada Hiraike, Osamu ^b   Kawana, Kei ^b   Fukayama, Masashi ^b   Fujiwara, Keiichi ^c   Yano, Tetsu ^e   Osuga, Yutaka ^b   Fujii, Tomoyuki ^b   Aburatani, Hiroyuki ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GENOMIC DNA; MEMBRANE PROTEIN; NEUROFIBROMIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ARID1A; PROTEIN P53; PROTEIN PIK3CA; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME ARM; CLEAR CELL CARCINOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; ENDOMETRIOID CARCINOMA; FEMALE; GENE CLUSTER; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MUTATION RATE; OMENTECTOMY; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALPINGOOOPHORECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CHROMOSOMAL INSTABILITY; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84934995522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128066     Document Type: Article

References (49)

1. Siegel R, Ward E, Brawley O, Jemal A. (2011) Cancer statistics, 2011: the impact of eliminating socio-economic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236. doi: 10.3322/caac.20121 PMID: 21685461
2. th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 Suppl 1: S161-192. PMID: 17161157
3. The Cancer Genome Atlas Research Network. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi: 10.1038/nature10166 PMID: 21720365
4. Bowtell DD. (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808. doi: 10.1038/nrc2946 PMID: 20944665
5. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, et al. (2008) Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 14:7645-7651 doi: 10.1158/1078-0432.CCR-08-1291 PMID: 19047089
6. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG. (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121: 407-15. doi: 10.1016/j.ygyno.2011.01.005 PMID: 21276610
7. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30: 249-255. PMID: 9088954
8. Shih IeM, Kurman RJ. (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518. PMID: 15111296
9. Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O. (2008) Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol 216:103-110. doi: 10.1002/path.2386 PMID: 18600856
10. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589. PMID: 10861437
11. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109: 370-376. doi: 10.1016/j.ygyno.2008.02.006 PMID: 18395777
12. Lee YY, Kim TJ, Kim MJ, Kim HJ, Song T, Kim MK, et al. (2011) Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 122: 541-547. doi: 10.1016/j.ygyno.2011.05.009 PMID: 21640372
13. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729. PMID: 12183431
14. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430. PMID: 16166416
15. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, et al. (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116-6126. PMID: 16144910
16. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512. PMID: 14633622
17. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, et al. (2008) Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 14: 32-40. doi: 10.1158/1078-0432.CCR-07-1614 PMID: 18172249
18. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, et al. (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752. doi: 10.1038/onc.2009.470 PMID: 20062075
19. Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, et al. (2010) DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 16: 1997-2008. doi: 10.1158/1078-0432. CCR-09-2105 PMID: 20233889
20. Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, et al. (2012) Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 118: 2846-2857. doi: 10.1002/cncr.26598 PMID: 22139760
21. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, et al. (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17:1521-1534. doi: 10.1158/1078-0432.CCR-10-1688 PMID: 21411445
22. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601. doi: 10.2353/ajpath.2009.081000 PMID: 19349352
23. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231. doi: 10.1126/science.1196333 PMID: 20826764
24. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543. doi: 10.1056/NEJMoa1008433 PMID: 20942669
25. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, et al. (2010) Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 11: 5120-5128. doi: 10.3390/ijms11125120 PMID: 21614196
26. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25: 615-624. doi: 10.1038/modpathol.2011.189 PMID: 22157930
27. Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, et al. (2012) Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics 5:47 doi: 10.1186/1755-8794-5-47 PMID: 23078675
28. Ishikawa S, Komura D, Tsuji S, Nishimura K, Yamamoto S, Panda B, et al. (2005) Allelic dosage analysis with genotyping microarrays. Biochem Biophys Res Commun 333: 1309-1314. PMID: 15982637
29. Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, et al. (2010) Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene 29: 1897-1908. doi: 10.1038/onc.2009.474 PMID: 20062086
30. Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S, et al. (2012) ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer 75: 119-125. doi: 10.1016/j.lungcan.2011.05.028 PMID: 21737174
31. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. (2011) Scikit-learn: Machine Learning in Python. J Mach Learn Res 12: 2825-2830
32. Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, et al. (2014) Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One 9:e87220 doi: 10.1371/journal.pone.0087220 PMID: 24504419
33. Morita Y, Wada-Hiraike O, Yano T, Shirane A, Hirano M, Hiraike H, et al. (2012) Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary. Reprod Biol Endocrinol 10:14 doi: 10.1186/1477-7827-10-14 PMID: 22357324
34. Oda K, Stokoe D, Taketani Y, McCormick F. (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673. PMID: 16322209
35. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, et al. (2008) PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68: 8127-8136. doi: 10.1158/0008-5472.CAN-08-0755 PMID: 18829572
36. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. (2011) Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 35: 625-632. doi: 10.1097/PAS.0b013e318212782a PMID: 21412130
37. Schvartzman JM, Sotillo R, Benezra R. (2010) Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10: 102-115. doi: 10.1038/nrc2781 PMID: 20094045
38. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861. doi: 10.1016/S1470-2045(11)70214-5 PMID: 21862407
39. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392. doi: 10.1056/NEJMoa1105535 PMID: 22452356
40. Berns EM, Bowtell DD. (2012) The changing view of high-grade serous ovarian cancer. Cancer Res 72: 2701-2704. doi: 10.1158/0008-5472.CAN-11-3911 PMID: 22593197
41. Wang ZC, Birkbak NJ, Culhane A, Drapkin R, Fatima A, Tian R, et al. (2012) Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 18: 5806-5815. doi: 10.1158/1078-0432.CCR-12-0857 PMID: 22912389
42. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719-725 doi: 10.1038/nrc3144 PMID: 21941283
43. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, et al. (2013) Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123: 3740-3750. doi: 10.1172/JCI68509 PMID: 23945238
44. Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. (2012) Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res 72: 3260-3269. doi: 10.1158/0008-5472.CAN-11-4141 PMID: 22552288
45. Yang Y, Wu J, Cai J, He Z, Yuan J, Zhu X, et al. (2015) PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells. Int J Cancer 136:E39-50 doi: 10.1002/ijc.29150 PMID: 25142862
46. Li CG, Nyman JE, Braithwaite AW, Eccles MR. PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. (2011) Oncogene 30:4824-4834 doi: 10.1038/onc.2011.190 PMID: 21602887
47. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, et al. (2014) A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res 20:711-723 doi: 10.1158/1078-0432.CCR-13-1256 PMID: 24218511
48. Chapman KB, Prendes MJ, Sternberg H, Kidd JL, Funk WD, Wagner J, et al. (2012) COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol 8:1031-1040 doi: 10.2217/fon.12.79 PMID: 22894674
49. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. (2009) High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2:21 doi: 10.1186/1755-8794-2-21 PMID: 19419571